reports
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants...
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by BridgeBio Pharma, Inc. (Nasdaq: BBIO), please note that some of the figures in the first paragraph were incorrect. The corrected release follows: BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s boa...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on January 23, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest o...
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due...
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 The transaction is part of our strategy to lower interest expense, reduce dilution, and significantly extend debt maturityOffering priced at 0.75% interest rate and 45% conversion premium PALO ALTO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, announced today the pricing of $550 million aggregate principal amount of ...
BridgeBio Continues Long Term Debt Management Strategy and Announces P...
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 -- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilution, and significantly extend debt maturity PALO ALTO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”), a new type of biopharmaceutical company focused on genetic diseases, announced today that it intends to offer, subject to market conditions...
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Mil...
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference - Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, driven by differentiated clinical data and growing real-world confidence - New TTR amyloid depleter antibody program announced to explore t...
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
BridgeBio to Participate in the J.P. Morgan Healthcare Conference PALO ALTO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT. To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeB...
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9...
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, January 9, 2026 at 8:00 am ET with Janet Legare, M.D., Professor in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitation Medicine in the Department of Pediatrics at the University of Wisconsin (UW) School of Med...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on December 18, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 9 new employees in restricted stock units for an aggregate of 29,472 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest o...
BridgeBio to Participate in December Investor Conferences
BridgeBio to Participate in December Investor Conferences PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: Piper Sandler Healthcare Conference, New York, NY: Fireside Chat on Tuesday, December 2 at 10:30 am ESTEvercoreISI HealthCONx Conference, Miami, FL: Fireside Chat on Wednesday, December 3 at 3:00 pm EST To ...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest ...
Acoramidis Significantly Reduces All-cause Mortality in the Overall AT...
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study69% risk reduction in ACM/ first CVH through Month 30 compared to placebo (p=0.016) and a 69% risk reduction in ACM through Month 42 (p=0.045) in ATTR-CM participants with the genetic variant p.Val142Ile (V142I, V1...
BridgeBio to Participate in November Investor Conferences
BridgeBio to Participate in November Investor Conferences PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host fireside chats at the following healthcare investor conferences: UBS Global Healthcare Conference, Palm Beach Gardens, FL: Fireside Chat on Monday, November 10 at 1:15 pm ESTJefferies Global Healthcare Conference, London, UK: Fireside Chat on Tuesday, November 18 at 11:00 am EST T...
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (...
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten moderated digital posters will be shared at the American Heart Association (AHA) Scientific Sessions 2025, taking place in New Orleans, LA from November 7 - 10, 2025. Moderated Digital Posters: Acoramidis Effect on All-Cause Mortalit...
BridgeBio Reports Third Quarter 2025 Financial Results and Business Up...
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates -$120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue -As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial treatment naïve patient segment -Attruby continues to differentiate clinically by proving its unique profile in new subpop...
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Pa...
BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 - The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered encaleret achieving both serum and urine calcium within the respective target ranges at Week 24 compared to 4% when on conventional therapy at Week 4 (p
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE St...
BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th PALO ALTO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced plans to release topline results of the autosomal dominant hypocalcemia type 1 (ADH1) CALIBRATE Phase 3 trial before the market opens on Wednesday, October 28, 2025. Members of management will host a conference call to discuss the data at 8:00 a.m. ET the same day. To access the live ...
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 ...
BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study - All primary and secondary interim analysis endpoints in FORTIFY Phase 3 study successfully achieved with well-tolerated safety profile consistent with the Company’s prior studies - Primary interim analysis endpoint, glycosylated αDG, significantly increased by 1.8x change from baseline at 3 months (p
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD...
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week PALO ALTO, Calif., Oct. 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will host two separate business update calls to share the following: Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar: Monday, October 27 a...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on October 2, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 11 new employees in restricted stock units for an aggregate of 23,884 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on...
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within ...
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM - By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.